ERBB2 and breast cancer: Another preclinical study demonstrated that the combination of CD47 mAb Hu5F9-G4 and trastuzumab in the treatment of Her2+ breast cancer cells significantly overcame the resistance to trastuzumab monotherapy and effectively inhibited tumor growth [157].